Recent Updates
Recently added Catalysts

Dexmedetomidine

Phase 3

ICU Delirium | Small molecule | Other |Baxter International Inc.|Last Updated: Jun 22, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment348
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03477344Dexmedetomidine After Cardiac Surgery for Prevention of DeliriumPHASE3 COMPLETED 348Jan 4, 2019Jun 29, 2021Jun 22, 20229 France
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Delirium
7 days

Occurrence of delirium diagnosed by the Confusion Assessment Method (CAM ICU) at any time in the first seven days after surgery

Secondary Endpoints
agitation with be assessed using the Richmond agitation and sedation score
7 days
length of ICU stay
28 days
length of hospital stay
28 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
DexmédétomidineACTIVE_COMPARATORIntravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
Sodium Chloride 0,9%PLACEBO_COMPARATORIntravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
Interventions
NameTypeDescription
DexmedetomidineDRUGIntravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
Sodium chloride 0.9%DRUGIntravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
Unlock Study Design Details
Eligibility Criteria
Age Range65 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites9

Inclusion Criteria: * patients aged 65 or more who undergo cardiac surgery on and off-pump: coronary artery bypass graft, cardiac valve replacement or both. * Consent signed Exclusion Criteria: * history of mental illness, dementia * inclusion in another study evaluating sedation or pain * length...

Countries:France
Unlock Eligibility Criteria